Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gross Profit (2016 - 2025)

Vanda Pharmaceuticals' Gross Profit history spans 13 years, with the latest figure at $53.4 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 5.51% year-over-year to $53.4 million; the TTM value through Dec 2025 reached $203.1 million, up 8.32%, while the annual FY2025 figure was $203.1 million, 8.32% up from the prior year.
  • Gross Profit for Q4 2025 was $53.4 million at Vanda Pharmaceuticals, roughly flat from $53.3 million in the prior quarter.
  • Across five years, Gross Profit topped out at $63.3 million in Q3 2021 and bottomed at $35.8 million in Q3 2023.
  • The 5-year median for Gross Profit is $53.3 million (2025), against an average of $52.1 million.
  • The largest annual shift saw Gross Profit tumbled 39.4% in 2023 before it rose 26.15% in 2024.
  • A 5-year view of Gross Profit shows it stood at $61.8 million in 2021, then fell by 5.73% to $58.2 million in 2022, then dropped by 28.21% to $41.8 million in 2023, then grew by 21.01% to $50.6 million in 2024, then increased by 5.51% to $53.4 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Gross Profit are $53.4 million (Q4 2025), $53.3 million (Q3 2025), and $49.9 million (Q2 2025).